全文获取类型
收费全文 | 721篇 |
免费 | 26篇 |
国内免费 | 77篇 |
专业分类
儿科学 | 31篇 |
妇产科学 | 62篇 |
基础医学 | 60篇 |
口腔科学 | 6篇 |
临床医学 | 97篇 |
内科学 | 155篇 |
皮肤病学 | 15篇 |
神经病学 | 64篇 |
特种医学 | 96篇 |
外科学 | 43篇 |
综合类 | 24篇 |
预防医学 | 9篇 |
眼科学 | 5篇 |
药学 | 62篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 93篇 |
出版年
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 9篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 10篇 |
2017年 | 5篇 |
2016年 | 13篇 |
2015年 | 19篇 |
2014年 | 21篇 |
2013年 | 26篇 |
2012年 | 29篇 |
2011年 | 30篇 |
2010年 | 17篇 |
2009年 | 22篇 |
2008年 | 11篇 |
2007年 | 67篇 |
2006年 | 27篇 |
2005年 | 36篇 |
2004年 | 26篇 |
2003年 | 13篇 |
2002年 | 12篇 |
2001年 | 18篇 |
2000年 | 22篇 |
1999年 | 15篇 |
1998年 | 24篇 |
1997年 | 34篇 |
1996年 | 26篇 |
1995年 | 23篇 |
1994年 | 19篇 |
1993年 | 15篇 |
1992年 | 6篇 |
1991年 | 10篇 |
1990年 | 11篇 |
1989年 | 19篇 |
1988年 | 19篇 |
1987年 | 11篇 |
1986年 | 14篇 |
1985年 | 15篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1982年 | 14篇 |
1981年 | 15篇 |
1980年 | 10篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1975年 | 10篇 |
1971年 | 2篇 |
排序方式: 共有824条查询结果,搜索用时 15 毫秒
1.
2.
3.
Kundel HL; Gefter W; Aronchick J; Miller W Jr; Hatabu H; Whitfill CH; Miller W Sr 《Radiology》1997,205(3):859
4.
The present paper is concerned with effects of the 4-10 sequence of the endogenous ACTH on electrophysiological measures of attention in humans. It was attempted to replicate previous findings of an impaired selective attention following administration of an analog of ACTH 4-9. The effect of this analog had been found to dominate in the beginning of the blocks of an attention task, but to fade away with time on task. In the present study, fourteen male students were tested in a dichotic listening paradigm, 40 min after intranasal application of either 0.4 mg ACTH 4-10, or placebo. Averaged auditory evoked potentials (AEPs) to attended and inattended tone pips, EEG power spectra, heart rate and blood pressure, and behavioral performance were measured during task performance. ACTH 4-10 appeared to slightly impair selective attention as indicated by AEP responses. In particular, the positive shift of the AEP waveforms to inattended stimuli was reduced at the beginning of each block of tone pips under ACTH 4-10. The pattern of actions resembled the effects observed after administration of the more potent synthetic analog of ACTH 4-9 in the previous experiment. Effects of ACTH 4-10 on the AEPs to inattended stimuli, however, differed from influences of the synthetic analog in that they did not affect a rather wide latency range but concentrated on the latency range of the P200 component. 相似文献
5.
U. Bickel J. Born H. L. Fehm M. Distler K. H. Voigt 《European journal of clinical pharmacology》1988,35(4):371-377
Summary A specific radioimmunoassay for the quantitative measurement of ACTH 4-10 and a procedure for its extraction from plasma have been developed.Its pharmacokinetics was studied in eight healthy male volunteers given ACTH 4-10 125 µg/kg body weight as a bolus i.v. injection, by infusion and intranasally. Following the i.v. bolus, plasma levels rapidly declined biexponentially, with half-lives of 0.39±0.05 min for the -phase and 3.84 ± 1.5 min for the -phase (mean±SD). The constant rate i.v. infusion yielded steady-state levels between 0.74 and 5.06 ng/ml plasma. Administered as intranasal spray, absorption of intact ACTH 4-10 was low and variable (maximal bioavailability 7.6%).The results are discussed in relation to the dose-dependent effects of ACTH 4-10 on the auditory evoked potential. 相似文献
6.
Molecular genetic characterization of XRCC4 function 总被引:2,自引:0,他引:2
XRCC4 is a generally expressed protein of 334 amino acids that is involved
in the repair of DNA double-strand breaks and in V(D)J recombination, but
its function is unknown. In this study, we have used a mutational approach
and the yeast two-hybrid method to perform an initial characterization of
this protein. We show that the XRCC4 protein is located in the nucleus. We
also demonstrate that several potential phosphorylation sites are not
required for XRCC4 function in a transient V(D)J recombination assay. In
addition, we show that XRCC4 forms a homodimer in vivo with the
homodimerization domain being located within amino acids 115-204. Finally,
we define a core domain of XRCC4 that functions in V(D)J recombination and
comprises amino acids 18-204. Potential functions of XRCC4 are discussed.
相似文献
7.
Rudolf Ernst Lang Karl-Heinz Voigt Horst Lorenz Fehm Ernst Friedrich Pfeiffer 《Neuroscience letters》1976,2(1):19-22
Hypothalamic nuclei were removed from frozen sections of rat brain and examined for their corticotropin-releasing activity. The highest concentration was measured in the median eminence. In addition there was significantly more activity detected in the nuclei paraventricularis, supraopticus, suprachiasmaticus and arcuatus than in the other nuclei. 相似文献
8.
Liu JQ; Bai XF; Shi FD; Xiao BG; Li HL; Levi M; Mustafa M; Wahren B; Link H 《International immunology》1998,10(8):1139-1148
Induction of mucosal tolerance by inhalation of soluble peptides with
defined T cell epitopes is receiving much attention as a means of
specifically down-regulating pathogenic T cell reactivities in autoimmune
and allergic disorders. Experimental autoimmune encephalomyelitis (EAE)
induced in the Lewis rat by immunization with myelin basic protein (MBP)
and Freund's adjuvant (CFA) is mediated by CD4+ T cells specific for the
MBP amino acid sequences 68-86 and 87-99. To further define the principles
of nasal tolerance induction, we generated three different MBP peptides
(MBP 68-86, 87-99 and the non- encephalitogenic peptide 110-128), and
evaluated whether their nasal administration on day -11, -10, -9, -8 and -7
prior to immunization with guinea pig MBP (gp-MBP) + CFA confers protection
to Lewis rat EAE. Protection was achieved with the encephalitogenic
peptides MBP 68-86 and 87-99, MBP 68-86 being more potent, but not with MBP
110-128. Neither MBP 68-86 nor 87-99 at doses used conferred complete
protection to gp-MBP-induced EAE. In contrast, nasal administration of a
mixture of MBP 68-86 and 87-99 completely blocked gp-MBP-induced EAE even
at lower dosage compared to that being used for individual peptides. Rats
tolerized with MBP 68-86 + 87-99 nasally showed decreased T cell responses
to MBP reflected by lymphocyte proliferation and IFN-gamma ELISPOT assays.
Rats tolerized with MBP 68-86 + 87-99 also had abrogated MBP-reactive
IFN-gamma and tumor necrosis factor-alpha mRNA expression in lymph node
cells compared to rats receiving MBP 110-128 nasally, while similar low
levels of MBP-reactive transforming growth factor-beta and IL-4 mRNA
expressing cells were observed in the two groups. Nasal administration of
MBP 68-86 + 87-99 only slightly inhibited guinea pig spinal cord
homogenate-induced EAE, and passive transfer of spleen mononuclear cells
from MBP 68-86 + 87-99-tolerized rats did not protect naive rats from EAE.
Finally, we show that nasal administration of MBP 68-86 + 87-99 can reverse
ongoing EAE induced with gp-MBP, although higher doses are required
compared to the dosage needed for prevention. In conclusion, nasal
administration of encephalitogenic MBP peptides can induce antigen-specific
T cell tolerance and confer incomplete protection to gp-MBP-induced EAE,
and MBP 68-86 and 87-99 have synergistic effects. Non-regulatory mechanisms
are proposed to be responsible for tolerance development after nasal
peptide administration.
相似文献
9.
Diana Lüftner Andreas D. Hartkopf Michael P. Lux Friedrich Overkamp Hans Tesch Adriana Titzmann Patrik Pschke Markus Wallwiener Volkmar Müller Matthias W. Beckmann Erik Belleville Wolfgang Janni Tanja N. Fehm Hans-Christian Kolberg Johannes Ettl Diethelm Wallwiener Andreas Schneeweiss Sara Y. Brucker Peter A. Fasching 《Breast care (Basel, Switzerland)》2021,16(2):108
BackgroundThe therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data.SummaryTo develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas.Key MessagesThis article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation. 相似文献
10.